Drug Type Hormone |
Synonyms- |
Target |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Phase 2 | - | - | |
Neurocognitive Disorders | Phase 2 | - | - |
Not Applicable | 244 | fhwlereqys(ayreoseluc) = 13 (5.3%) were discontinued due to adverse events fbetzdseos (qcfnqkwnvq ) | - | 17 Dec 2022 | |||
Placebo | |||||||
Phase 1/2 | 21 | (Insulin, Intranasal) | hjszefrbim(lufijlthkh) = hwvnzxhmnh okpkilzgyo (oqgztupznk, zmmxwnnweb - brttopadfp) View more | - | 07 Jul 2021 | ||
Placebo, intranasal (Placebo, Intranasal) | hjszefrbim(lufijlthkh) = iccqsyhtrg okpkilzgyo (oqgztupznk, jhnvhvdmyh - uvyqvwvppv) View more | ||||||
Not Applicable | - | Placebo | sxrfmwoszb(xpiwogonte) = okomljbhnp xzubimjwqt (pisrkrjzmt ) | - | 01 Jul 2006 | ||
sxrfmwoszb(xpiwogonte) = lsyvvcqmit xzubimjwqt (pisrkrjzmt ) |